Form 8-K - Current report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

FORM 8-K

______________________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2024

______________________

SEMLER SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-36305	26-1367393
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


2340-2348 Walsh Avenue, Suite 2344 Santa Clara, CA		95051
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 774-4211

______________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	SMLR	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2024, Semler Scientific, Inc. issued a press release announcing its financial results for the second quarter and six months ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

The information contained in this Item 9.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Semler Scientific, Inc., dated August 5, 2024.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	SEMLER SCIENTIFIC, INC.

Date: August 5, 2024	By:	/s/ Renae Cormier
		Name: Renae Cormier
		Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

Exhibit 99.1

Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases

Santa Clara, CA – August 5, 2024 – Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the second quarter ended June 30, 2024. In addition, the Company announced the purchase of an additional 101 bitcoins for an aggregate amount of $6.0 million. Since announcing the adoption of a bitcoin treasury strategy on May 28, 2024, the Company has purchased 929 bitcoins for a total of $63.0 million.

“We are pleased to report strong income from operations of $5.4 million in the second quarter,” said Doug Murphy-Chutorian, MD, chief executive officer of Semler Scientific. “We remain laser focused on acquiring and holding bitcoin, while supporting and expanding our healthcare business.”

“We are very encouraged by the strong positive reaction to our recent announcement of a bitcoin treasury strategy,” said Eric Semler, chairman of Semler Scientific. “We continue to firmly believe that bitcoin is a compelling investment and plan on acquiring additional bitcoins with our cash from operations, as well as with cash generated from the sale of securities under our $150.0 million shelf registration statement, once effective.”

FINANCIAL RESULTS

For the second quarter ended June 30, 2024, compared to the corresponding period of 2023, Semler Scientific reported:

●

Revenues of $14.5 million, a decrease of $4.1 million, or 22%, compared to $18.6 million.

●

Cost of revenues of $1.3 million, an increase of $0.1 million, or 3%, compared to $1.2 million

●

Total operating expenses, which include cost of revenues, of $9.1 million, a decrease of $2.3 million, or 20%, compared to $11.4 million.

●

Income from operations of $5.4 million, a decrease of $1.8 million, or 25%, compared to $7.2 million.

●

Pre-tax net income of $1.1 million (which includes the change in fair value on our bitcoin holdings of negative $5.1 million), a decrease of $6.6 million, or 85%, compared to $7.7 million.

●

Income tax expense of $1.1 million, or an effective tax rate of 99%, compared to $1.8 million, or an effective tax rate of 23%.

●

Net income of $11 thousand, or breakeven, a decrease of $5.9 million, or 100%, compared to net income of $5.9 million, or $0.88 per basic share and $0.75 per diluted share.

Semler Scientific’s three largest customers (including their affiliates) comprised 44%, 27% and 11% of second quarter 2024 revenues, respectively, and its two largest customers comprised 37% and 34% of second quarter 2023 revenues, respectively.

BITCOIN HOLDINGS

On May 28, 2024, Semler Scientific announced the initial purchase of 581 bitcoins for an aggregate amount of $40.0 million. On June 6, 2024, the Company announced the purchase of an additional 247 bitcoins for an aggregate amount

of $17.0 million. On June 28, 2024, the Company purchased an additional 49 bitcoins for an aggregate cost of $3.0 million. As of June 30, 2024, the Company held 877 bitcoins with a fair value of $54.9 million, which reflects a cumulative reduction in fair value of $5.1 million.

Subsequently through August 5, 2024, the Company has purchased an additional 52 bitcoins for an aggregate cost of $3.0 million. Semler Scientific’s total holdings as of August 5, 2024 are 929 bitcoins for an aggregate purchase amount of $63.0 million. All purchase amounts include fees and expenses.

Notice of Conference Call

Semler Scientific will host a conference call today at 4:30 p.m. ET. The call will address results of the second quarter ended June 30, 2024, as well as provide a business update on Semler Scientific’s strategies for the near-term future. Questions can be submitted prior to the start of the call to ir@semlerscientific.com.

Participants are encouraged to pre-register for the conference call using the following link: https://dpregister.com/sreg/10190580/fcfdde76dc. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or who are unable to pre-register may dial in by calling:

Domestic callers: (833) 816-1161

International callers: (412) 317-0717

Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific’s website at www.semlerscientific.com.

Semler Scientific, Inc.

Condensed Statements of Income

Unaudited

(In thousands of U.S. Dollars, except share and per share data)


	For the three months ended June 30,				For the six months ended June 30,
	2024		2023		2024		2023

Revenues	$	14,465	$	18,605	$	30,368	$	36,811
Operating expenses:
Cost of revenues		1,255		1,219		2,501		2,488
Engineering and product development		1,440		1,762		2,578		3,392
Sales and marketing		3,456		4,985		7,131		10,177
General and administrative		2,964		3,459		5,832		7,318
Total operating expenses		9,115		11,425		18,042		23,375
Income from operations		5,350		7,180		12,326		13,436
Interest and dividend income		714		597		1,534		1,080
Change in fair value of notes held for investment		128		(111)		128		(217)
Change in fair value of digital assets		(5,055)		—		(5,055)		—
Other (expense) income, net		(4,213)		486		(3,393)		863
Pre-tax income		1,137		7,666		8,933		14,299
Income tax provision		1,126		1,787		2,849		3,451
Net income	$	11	$	5,879	$	6,084	$	10,848
Net income per share, basic	$	0.00	$	0.88	$	0.88	$	1.62
Weighted average number of shares used in computing basic net income per share		6,944,664		6,707,341		6,918,709		6,704,306
Net income per share, diluted	$	0.00	$	0.75	$	0.78	$	1.38
Weighted average number of shares used in computing diluted net income per share		7,795,149		7,867,001		7,789,101		7,887,584

Semler Scientific, Inc.

Condensed Balance Sheets

(In thousands of U.S. Dollars, except share and per share data)


	June 30,		December 31,
	2024		2023
		Unaudited
Assets
Current Assets:
Cash and cash equivalents	$	7,332	$	57,200
Restricted cash		132		132
Trade accounts receivable, net of allowance for credit losses of $243 and $287, respectively		7,470		6,125
Short-term notes held for investments		6,100		—
Inventory, net		385		445
Prepaid expenses and other current assets		2,271		2,042
Total current assets		23,690		65,944
Assets for lease, net		1,768		2,285
Property and equipment, net		620		720
Long-term investments		512		512
Notes held for investment		—		5,372
Intangible digital assets		54,945		—
Other non-current assets		127		270
Deferred tax assets, net of valuation allowance of $1,207 and $0, respectively		3,124		2,962
Total assets	$	84,786	$	78,065

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	227	$	402
Accrued expenses		5,086		4,502
Deferred revenue		840		1,120
Other short-term liabilities		211		176
Total current liabilities		6,364		6,200

Long-term liabilities:
Other long-term liabilities		24		70
Total long-term liabilities		24		70
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value; 50,000,000 shares authorized; 7,202,146 and 7,099,441 shares issued, and 6,987,724 and 6,885,019 shares outstanding (treasury shares of 214,422 and 214,422), respectively		7		7
Additional paid-in capital		12,504		11,985
Retained earnings		65,887		59,803
Total stockholders’ equity		78,398		71,795

Total liabilities and stockholders’ equity	$	84,786	$	78,065

Semler Scientific, Inc.

Condensed Statements of Cash Flows

Unaudited

(In thousands of U.S. Dollars)


	Six months ended June 30,
	2024		2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	6,084	$	10,848

Reconciliation of Net Income to Net Cash Provided by Operating Activities:
Depreciation		346		279
Deferred tax expense		(163)		(207)
Loss on disposal of assets for lease		319		114
Gain on short-term investments		—		(237)
Allowance for credit losses		(44)		92
Change in fair value of notes held for investment		(128)		217
Change in fair value of digital assets		5,055		—
Stock-based compensation		295		860
Changes in Operating Assets and Liabilities:
Trade accounts receivable		(1,292)		(2,240)
Inventory		60		(7)
Prepaid expenses and other current assets		(135)		(950)
Other non-current assets		43		106
Accounts payable		(175)		(326)
Accrued expenses		584		3,495
Other current and non-current liabilities		(291)		13
Net Cash Provided by Operating Activities		10,558		12,057

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment		(48)		(260)
Purchase of notes held for investment		(500)		(500)
Purchase of digital assets		(60,000)		—
Proceeds from maturities of short-term investments		—		57,707
Purchase of short-term investments		—		(49,728)
Purchase of assets for lease				(674)
Net Cash (Used in) Provided by Investing Activities		(60,548)		6,545

CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchase of warrants		—		(1,949)
Taxes paid related to net settlement of equity awards		(45)		(172)
Stock issuance expenses		(102)		—
Proceeds from exercise of stock options		269		—
Net Cash Provided by (Used in) Financing Activities		122		(2,121)
(DECREASE) INCREASE IN CASH		(49,868)		16,481
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD		57,332		23,014
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	$	7,464	$	39,495

Semler Scientific, Inc.

Digital Assets- Additional Information

Rollforward of bitcoin holdings

Unaudited


	Source of Capital Used to Purchase Bitcoin	Digital Assets at Cost (in thousands)		Change in fair Value (in thousands)		Digital Assets at Fair Value (in thousands)		Approximate Number of Bitcoin Held	Approximate Average Purchase Price Per Bitcoin
Balance as of March 31, 2024		$	—	$	—	$	—	—	$	—
Digital assets purchased	(a)		60,000		—		60,000	877		68,436
Change in fair value of the digital assets			—		(5,055)		(5,055)	—		—
Balance as of June 30, 2024		$	60,000	$	(5,055)	$	54,945	877	$	68,436

(a)

Cash from operations

About Semler Scientific, Inc.:

Semler Scientific, Inc. is a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient’s risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific also invests in bitcoin and has adopted bitcoin as its primary treasury asset. Additional information about Semler Scientific can be found at www.semlerscientific.com.

Forward-Looking Statements

This press release contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “believe,” “goal,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include express or implied statements regarding expansion of the healthcare business; seeking a new 510(k) clearance for QuantaFlo with expanded indications for use; purchase of additional bitcoin; value of bitcoin and ability to execute on the bitcoin treasury strategy; among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific’s actual results to differ materially from those discussed here, such as such as risks inherent with investing in bitcoin, including bitcoin's volatility; risk of implementing a new bitcoin treasury strategy; risk that insurance plans and other customers will not continue to license its cardiovascular testing products; risk of changes in the reimbursement landscape for its customers including related to the Centers for Medicare and Medicaid Services (CMS) rate announcement; risk of obtaining a new 510(k) clearance for expanded indications; along with those other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore,

all such statements are made as of the date of this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

No Offer or Solicitation

This press release does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Semler Scientific, Inc., nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

INVESTOR CONTACT:

Renae Cormier

Chief Financial Officer

ir@semlerscientific.com

SOURCE: Semler Scientific, Inc.

Document and Entity Information	Aug. 05, 2024
Document and Entity Information [Abstract]
Document Type	8-K
Document Period End Date	Aug. 05, 2024
Entity File Number	001-36305
Entity Registrant Name	SEMLER SCIENTIFIC, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1367393
Entity Address, Address Line One	2340-2348 Walsh Avenue, Suite 2344
Entity Address, City or Town	Santa Clara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	877
Local Phone Number	774-4211
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	SMLR
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false
Entity Central Index Key	0001554859
Amendment Flag	false